- Home
- ADCT vs ALLT Comparison
ADCT vs ALLT Comparison
Compare ADCT & ALLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- ALLT
- Stock Information
- Founded
- ADCT 2011
- ALLT 1996
- Country
- ADCT Switzerland
- ALLT Israel
- Employees
- ADCT N/A
- ALLT N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- ALLT Telecommunications Equipment
- Sector
- ADCT Health Care
- ALLT Telecommunications
- Exchange
- ADCT Nasdaq
- ALLT Nasdaq
- Market Cap
- ADCT 380.2M
- ALLT 342.5M
- IPO Year
- ADCT 2020
- ALLT 2006
- Fundamental
- Price
- ADCT $4.54
- ALLT $10.96
- Analyst Decision
- ADCT Strong Buy
- ALLT Buy
- Analyst Count
- ADCT 6
- ALLT 1
- Target Price
- ADCT $7.80
- ALLT N/A
- AVG Volume (30 Days)
- ADCT 1.1M
- ALLT 477.5K
- Earning Date
- ADCT 11-06-2025
- ALLT 11-18-2025
- Dividend Yield
- ADCT N/A
- ALLT N/A
- EPS Growth
- ADCT N/A
- ALLT N/A
- EPS
- ADCT N/A
- ALLT N/A
- Revenue
- ADCT $77,246,000.00
- ALLT $95,342,000.00
- Revenue This Year
- ADCT $13.47
- ALLT $10.64
- Revenue Next Year
- ADCT $5.88
- ALLT $15.76
- P/E Ratio
- ADCT N/A
- ALLT N/A
- Revenue Growth
- ADCT 15.73
- ALLT 4.74
- 52 Week Low
- ADCT $1.05
- ALLT $2.78
- 52 Week High
- ADCT $4.67
- ALLT $11.42
- Technical
- Relative Strength Index (RSI)
- ADCT 74.76
- ALLT 66.14
- Support Level
- ADCT $4.15
- ALLT $10.56
- Resistance Level
- ADCT $4.67
- ALLT $11.41
- Average True Range (ATR)
- ADCT 0.25
- ALLT 0.51
- MACD
- ADCT 0.08
- ALLT 0.05
- Stochastic Oscillator
- ADCT 82.86
- ALLT 75.73
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About ALLT Allot Ltd.
Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.